[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Abbott Nutrition\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,67,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100551165","infant-formula-in-infants-and-children-with-cows-milk-allergy-100551165",false,"NCT06456541","Infant Formula in Infants and Children With Cow's Milk Allergy","Determination of Hypoallergenicity of an Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy","Inclusion Criteria:\n\n* Participant's parent(s) is\u002Fare willing for their child to undergo confirmatory testing or must have had at least one of the following within 6 months of enrollment:\n\n  1. Physician diagnosis of IgE-mediated CMA, according to the participant's clinical history (e.g. gastrointestinal symptoms, hives, respiratory symptoms or angioedema) AND, detectable serum milk-specific IgE \\>0.7 kUᴀ\u002FL or positive skin prick test wheal ≥5 mm;\n  2. Documentation of milk-specific serum IgE \\>15 kUᴀ\u002FL or \\> 5 kUᴀ\u002FL if younger than 1 year;\n  3. Documented cow's milk skin prick test wheal \\>10mm;\n  4. Physician-supervised oral food challenge that elicited immediate, objective, allergic symptoms.\n* Participant's parent(s) agree for their child to stop oral steroid use within 14 days and antihistamine use within 7 days prior to confirmation of diagnosis and food challenges.\n* Participant had followed a strict cow's milk protein-free diet for at least 2 weeks prior to enrollment.\n* Parent(s) confirm their intention not to administer any products containing cow's milk protein during the study.\n* Participant is between 3 months and 12 years of age at enrollment.\n* Participant's parent(s) has voluntarily signed and dated an Informed Consent Form (ICF), approved by an Independent Ethics Committee\u002FInstitutional Review Board (IEC\u002FIRB) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.\n\nExclusion Criteria:\n\n* Participant is partially or exclusively breastfed at the time of enrollment.\n* Participant is consuming an amino acid-based formula due to failure on an extensively hydrolyzed formula.\n* Significant chronic medical diseases including major chromosomal or congenital anomalies, gastrointestinal diseases, or abnormalities other than CMA, immunodeficiencies, unstable asthma, eczema and\u002For food allergies treated with biologics (omalizumab or other monoclonal antibody), FPIES, eosinophilic esophagitis, and severe uncontrolled eczema.\n* Previous severe anaphylactic reaction to cow's milk within the last two years.,\n* An adverse medical history or current condition that is thought by the investigator to have potential for effects on tolerance or the hypoallergenicity test.\n* Participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent.\n* Participant is consuming baked milk products.\n* Use of and\u002For changing dose of high potency steroids.","ALL","3 Months","12 Years",{"count":20,"type":21},61,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a multi-center, randomized, double-blinded, placebo-controlled food challenge to be conducted in infants and children with confirmed IgE-mediated cow's milk allergy (CMA), followed by a 7-day open feeding of the experimental formula.",[27],"Cow's Milk Allergy","RECRUITING","2026-05-11",{"date":31,"type":32},"2026-05-13","ACTUAL",{"date":34,"type":32},"2024-10-01",{"date":36,"type":21},"2029-01",{"name":38,"class":39},"Abbott Nutrition","INDUSTRY",9,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100633301","stunting-and-targeting-reduction-of-impaired-growth-in-kids-effectively-100633301","NCT07524907","Stunting and Targeting Reduction of Impaired Growth in Kids Effectively","STRIKE: Stunting and Targeting Reduction of Impaired Growth in Kids Effectively: A Community Engaged Comprehensive, Multi-Faceted Nutrition Quality Improvement Program","STRIKE","Household Component\n\nInclusion\n\n* Children aged 1-5 years experiencing stunting or its risk (defined as HAZ ≤ -1 SD at baseline)\n* Children's legal guardian agrees to participate in the study\n* Full term pregnancy (defined as ≥ 37 weeks gestation and ≥ 2500g birth weight)\n* Residence in study area attending Children International (NGO) centers\n\nExclusion\n\n• Children who have current medical conditions requiring hospitalization: gastrointestinal tract infections or inflammatory bowel disease; active tuberculosis; acute hepatitis B or C; human immunodeficiency virus OR malignancy; cystic fibrosis; immunodeficiency syndromes, congenital abnormalities of the respiratory tract, such as lung and respiratory cilia; an unsuspected foreign body in the respiratory tract; asthma; heart abnormalities; abdominal hernias; and known metabolic disorders, renal impairment, or rheumatic diseases and diabetes\n\n* Congenital condition\n* Children with disabilities such as cerebral palsy, autism spectrum disorder, neurodegenerative disorders\n* Children with chronic or acute infections e.g. HIV, malaria\n* Children who are taking medications or other agents that could potentially affect body weight, including diuretics, appetite stimulants, steroids, and growth hormones\n* Children who have genetic conditions impacting weight status such as but not limited to: Bardet-Biedl Syndrome, Prader-Willi Syndrome\n* Children already enrolled in a nutrition program that includes a supplement\n* Participant has an allergy or intolerance to any ingredient in the study supplement, as reported by the parent.\n* Children with sleep disorders such as but not limited to: obstructive sleep apnea, insomnia, parasomnias (sleepwalking, night terrors, bedwetting), delayed sleep phase syndrome, behavioral sleep disorders, circadian rhythm disorders\n* Mental health disorders such as but not limited to: anxiety, depression\n\nOrganization Component\n\nInclusion\n\n* NGO staff taking part in nutrition screenings\n* Agrees to participate in survey\n\nExclusion\n\n* Not involved in the implementation of the study\n* Not involved in working with pediatric stunting or its risk\n* Declines participation in survey","1 Year","5 Years",{"count":52,"type":21},150,"OBSERVATIONAL","The objective of this prospective, real-world evidence\u002Fpragmatic study with a quality improvement program approach is to evaluate the feasibility and effectiveness of a community-engaged nutrition-focused program utilizing nutrition screening, education, supplementation and continuous follow up for children and their families.",[56],"Malnutrition (Calorie)","NOT_YET_RECRUITING","2026-04-06",{"date":60,"type":32},"2026-04-13",{"date":62,"type":21},"2026-06",{"date":64,"type":21},"2028-01",{"name":38,"class":39},1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":66},"100612695","malnutrition-screening-study-100612695","NCT07256925","Malnutrition Screening Study","LEVEL-UP Turkish Adult Outpatient Screening Study","Inclusion Criteria:\n\n* Participant has voluntarily signed and dated an informed consent form (ICF), approved by an Independent Ethics Committee (IEC)\u002FInstitutional Review Board (IRB), and provided other applicable privacy regulation authorization (if applicable) prior to any participation in the study.\n* Participant is ≥ 18 years of age who attend hospital clinics (medical and radiation oncology, neurology, and geriatrics clinics) as an outpatient for any reason.\n\nExclusion Criteria:\n\n* NA","18 Years",{"count":76,"type":21},7500,"This is a non-interventional, cross-sectional, non-randomized, observational study to screen for the risk of malnutrition and sarcopenia in outpatients aged 18 and over who attend hospital clinics for any reason in Turkey.",[79,80],"Malnutrition, Calorie","Sarcopenia","2026-01-28",{"date":83,"type":32},"2026-01-29",{"date":85,"type":32},"2026-01-12",{"date":87,"type":21},"2026-07",{"name":38,"class":39},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":109},"100481666","preterm-infants-fed-a-human-milk-fortifier-100481666","NCT05551975","Preterm Infants Fed a Human Milk Fortifier","Growth and Tolerance of Preterm Infants Fed an Experimental Human Milk Fortifier","Inclusion Criteria:\n\n* Birth weight between 700 g-1500 g.\n* ≤ 32 weeks and 0 days GA at birth.\n* Participant has been classified as appropriate for GA (AGA).\n* Enteral feeding of human milk must be initiated by 21 days of life (birth date is day of life 0)\n* Mother agrees to provide human milk as the exclusive feeding during the study period; use of donor milk is permitted if fortified with study fortifier and use of mother's own milk (when available) is prioritized.\n* Parent(s) agrees to allow infant to receive both human milk and study HMF.\n* Singleton or twin births only.\n* Infant's parent(s) or a LAR has voluntarily signed and dated an ICF, approved by an IRB\u002FIEC and provided HIPAA (or other applicable privacy regulation) authorization prior to any participation in the study.\n\nExclusion Criteria:\n\n* Enteral feeding of preterm infant formula or HMF for \\> 7 days.\n* Expected to be transferred to another facility within 30 days of randomization.\n* Serious congenital abnormalities or underlying disease that may affect growth and development.\n* 5-minute APGAR ≤ 4.\n* Receiving systemic steroids at time of randomization.\n* Receiving probiotics at time of randomization.\n* Grade Ill or IV PVH\u002FIVH.\n* Dependent on invasive ventilation at time of randomization.\n* Maternal incapacity.\n* Mother or infant is currently receiving treatment consistent with HIV therapy.\n* Documentation of maternal use of alcohol or marijuana during pregnancy that in the opinion of the physician is considered abuse.\n* Positive toxicology report for cocaine, opiates, or methamphetamine in mother or infant.\n* Infant has a history of major surgery (intra-thoracic or intra-abdominal procedures or other surgery requiring general anesthesia).\n* Asphyxia defined as progressive hypoxemia and hypercapnia with significant metabolic acidemia characterized by APGAR score \\\u003C3 at 10 minutes, seizures within the first 12 hours of life, or a cord blood gas \\\u003C 7.0 and seizures and\u002For severe tonic abnormalities in the first 12 hours of life.\n* Confirmed NEC (Bell's Stage II or III).\n* Confirmed current sepsis.\n* Infant has any other condition that, in the opinion of the investigator, precludes participation in the study.\n* Participation in another study that has not been approved as a concomitant study by AN.\n* Participant has an allergy or intolerance to any ingredient in study fortifier.",{"count":97,"type":21},321,[24],"This is a double-blind, randomized, multi-center, controlled, parallel study to evaluate the growth and tolerance of preterm infants fed human milk fortifier (HMF).",[101],"Growth","2024-06-26",{"date":104,"type":32},"2024-06-28",{"date":106,"type":21},"2024-09",{"date":64,"type":21},{"name":38,"class":39},14,""]